Takeda’s Ninlaro becomes available in U.S.
CAMBRIDGE, Mass. — Takeda Pharmaceutical Co. has released Ninlaro capsules (ixazomib), a blood cancer medication, in the United States. Takeda said Friday that Ninlaro is the first and only oral proteasome inhibitor. In combination with lenalidomide and dexamethasone, Ninlaro is indicated for the treatment of patients with multiple myeloma, a plasma cell cancer, who have received at least one
